Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Rossing

Showing results (71-80 of 131) with videos related to

Pageof 14
Sort By:
Diabetes|July 1, 1997
Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathyF S Nielsen, P Rossing, M A Gall, et al.
Diabetes|September 1, 1994
Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathyF S Nielsen, P Rossing, M A Gall, et al.
Kidney International. Supplement|January 4, 1998
Kidney function after withdrawal of long-term antihypertensive treatment in diabetic nephropathyH P Hansen, F S Nielsen, P Rossing, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|September 25, 2001
Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin-dependent diabetic patients with diabetic nephropathyB Myrup, P Rossing, T Jensen, et al.
Kidney International. Supplement|July 21, 1999
Progression of diabetic nephropathy in normotensive type 1 diabetic patientsP Jacobsen, K Rossing, L Tarnow, et al.
Kidney International|June 16, 2006
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathyK J Schjoedt, K Rossing, T R Juhl, et al.
Kidney International|April 29, 1998
Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathyP Jacobsen, K Rossing, P Rossing, et al.
Diabetes Care|March 31, 1999
Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up studyH H Parving, L Tarnow, F S Nielsen, et al.
Journal of Internal Medicine|May 17, 2014
Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetesS Theilade, S Lyngbaek, T W Hansen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 1, 2001
Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1P Hovind, L Tarnow, P Rossing, et al.
Pageof 14

Showing results (71-80 of 131) with videos related to

Sort By:
Pageof 14
Diabetes|July 1, 1997
Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathyF S Nielsen, P Rossing, M A Gall, et al.
Diabetes|September 1, 1994
Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathyF S Nielsen, P Rossing, M A Gall, et al.
Kidney International. Supplement|January 4, 1998
Kidney function after withdrawal of long-term antihypertensive treatment in diabetic nephropathyH P Hansen, F S Nielsen, P Rossing, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|September 25, 2001
Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin-dependent diabetic patients with diabetic nephropathyB Myrup, P Rossing, T Jensen, et al.
Kidney International. Supplement|July 21, 1999
Progression of diabetic nephropathy in normotensive type 1 diabetic patientsP Jacobsen, K Rossing, L Tarnow, et al.
Kidney International|June 16, 2006
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathyK J Schjoedt, K Rossing, T R Juhl, et al.
Kidney International|April 29, 1998
Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathyP Jacobsen, K Rossing, P Rossing, et al.
Diabetes Care|March 31, 1999
Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up studyH H Parving, L Tarnow, F S Nielsen, et al.
Journal of Internal Medicine|May 17, 2014
Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetesS Theilade, S Lyngbaek, T W Hansen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 1, 2001
Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1P Hovind, L Tarnow, P Rossing, et al.
Pageof 14